Financials
Financial year 2025
medicines for europe from Elsene, company number BE0449332209, closed financial year 2025 with a result of € -972,902 after tax. For that financial year medicines for europe recorded a gross margin of € 744,308 and equity of € 2.5 million. Compared with financial year 2024, the result moved from € 147,365 to € -972,902. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 31, 2026.
€ 2.5 million
▼ 28% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -972,902
▼ still € 147,365 profit in 2024
Profit after tax over the fiscal year.
€ 3.4 million
▼ 14% vs 2024
Cash and bank balances on the last day of the fiscal year.
People and assets in 2025
18
▲ 3 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 1.7 million
▲ 17% vs 2024
€ 95,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 20,548
▼ 39% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 423,407
▲ 81% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 272,403
▲ 15% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 1,471,974 | € 1,691,084 | € 1,666,991 | € 744,308 | ▼ 55% |
| Profit after taxes | € 284,750 | € 339,420 | € 147,365 | € -972,902 | ▼ € 1.1 million |
| Equity | € 3,008,599 | € 3,348,020 | € 3,495,384 | € 2,522,483 | ▼ 28% |
| Total debts | € 651,114 | € 731,393 | € 669,983 | € 1,155,571 | ▲ 72% |
| Cash | € 3,147,625 | € 1,718,891 | € 3,921,912 | € 3,384,525 | ▼ 14% |
| Land & buildings | € 8,023 | € 6,585 | € 5,147 | € 3,708 | ▼ 28% |
| Retained profit | € 3,008,599 | € 3,348,020 | € 3,495,384 | € 2,522,483 | ▼ 28% |
| Balance sheet total | € 3,659,713 | € 4,079,412 | € 4,165,367 | € 3,678,054 | ▼ 12% |
| Employees (FTE) | 13 | 14.8 | 15 | 18 | ▲ 3 |
Key figures of medicines for europe, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to medicines for europe?
What happened at medicines for europe in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 972,902 (▼ € 1.1 million vs 2024). Source: NBB ↗
- Michel NITKA became a director. NBB
- Anish MEHTA became a director. NBB
- Christos GALLIS became a director. NBB
- Philippe DRESCHLE stepped down as director. NBB
- Markus SIEGER stepped down as director. NBB
- Stephen EDER stepped down as director. NBB
- Christophe DELENTA became a director. NBB
In short
From € 284,750 profit in 2022 to € 972,902 loss in 2025.
Paid € 1,014 in corporate taxes since 2022.
Best year ever: 2023, with € 339,420 profit.
On average € 41,400 of value added per employee in 2025.
A new publication or filing at medicines for europe? We notify you, reason included.
Follow medicines for europeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind medicines for europe are Steffen SALTOFTE, Bork BRETTHAUER, Michel NITKA, Elisabeth STAMPA JAGER, Christophe DELENTA and Lucas SIGMAN.
Directors
According to the 2025 annual accounts
Steffen SALTOFTE
Chairman of the board
since 2023
Bork BRETTHAUER
Director
since 2023
Michel NITKA
Director
since 2025
Elisabeth STAMPA JAGER
Vice-chairman of the board
since 2023
Christophe DELENTA
Secretaris
since 2024
Lucas SIGMAN
Director
since 2023
Anish MEHTA
Director
since 2025
Paul TREWELL
Director
since 2023
Arthur CWIOK
Director
since 2023
Theodore TRYFON
Vice-chairman of the board
since 2023
Christos GALLIS
Director
since 2025
Martha CHRISTOPOULOU
Director
since 2023
Michele UDA
Director
since 2023
Jean HERMANS
Director
since 2023
Marc CROUTON
Vice-chairman of the board
since 2024
Philippe DRESCHLE
Director
since 2023 · until 2025
Stephen EDER
Director
since 2023 · until 2025
Markus SIEGER
Chairman of the board
since 2023 · until 2025
Establishments
Establishment units
Physical locations of this company
Kapitein Crespelstraat 30 box A03
1050 Elsene
Aarlenstraat 50
1000 Brussel
Active since 8 March 2016
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0449.332.209
- VAT number
- BE 0449.332.209
- Registered office
- Kapitein Crespelstraat 30 bus A03, 1050 Elsene
- Names & denominations
- medicines for europe
- Enterprise type
- Rechtspersoon
- Legal form
- International non-profit association
- Legal situation
- Normale toestand
- Start date
- 26 October 1992
- Peppol
- Active · Active since 3 Dec 2025
- Activities · NACE
Activiteiten van beroepsorganisaties
Beroepsorganisaties